Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 years

[1]  C. Sotiriou,et al.  Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. , 2016, JAMA oncology.

[2]  Peter A. Fasching,et al.  Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer , 2016, Clinical Cancer Research.

[3]  A. Schneeweiss,et al.  Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. , 2016, The Lancet. Oncology.

[4]  Peter A Kaufman,et al.  Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer , 2014, Cancer.

[5]  M. Rezai,et al.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[6]  John M S Bartlett,et al.  HER2 testing: current status and future directions. , 2014, Cancer treatment reviews.

[7]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[8]  S. Tolaney.  New HER2-Positive Targeting Agents in Clinical Practice , 2014, Current Oncology Reports.

[9]  E. Perez,et al.  Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study , 2014, Breast Cancer Research and Treatment.

[10]  M. Rezai,et al.  Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  M. Rezai,et al.  Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). , 2013, European journal of cancer.

[12]  P. Fasching,et al.  HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer , 2013, Breast Cancer Research.

[13]  M. Rezai,et al.  Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. , 2012, The Lancet. Oncology.

[14]  Tanja Fehm,et al.  Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. , 2012, The New England journal of medicine.

[15]  H. Kreipe,et al.  Quality assessment of HER2 testing by monitoring of positivity rates , 2011, Virchows Archiv.

[16]  Carsten Denkert,et al.  Quantitative Determination of Estrogen Receptor, Progesterone Receptor, and HER2 mRNA in Formalin-fixed Paraffin-embedded Tissue—A New Option for Predictive Biomarker Assessment in Breast Cancer , 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[17]  C. Denkert,et al.  Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765) , 2011, Breast Cancer Research and Treatment.

[18]  Hiltrud Brauch,et al.  Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. , 2010, Clinical chemistry.

[19]  Peter A Fasching,et al.  Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Rezai,et al.  Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Uwe Rogel,et al.  RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. , 2009, Clinical chemistry.

[23]  J. Baselga,et al.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.

[24]  S. Loibl,et al.  Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. , 2008, Journal of the National Cancer Institute.

[25]  S. Loibl,et al.  Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. , 2008, Journal of the National Cancer Institute.

[26]  A. Chaudhuri,et al.  HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer , 2008 .

[27]  L. Huo.  HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial , 2007 .

[28]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[29]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[30]  W. Sauerbrei,et al.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[31]  I. Zuna,et al.  In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  A. Ullrich,et al.  The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.

[33]  Greg Yothers,et al.  Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. , 2002, Journal of the National Cancer Institute.

[34]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.